Memantine - an NMDA receptor antagonist, helps improve specific brain functions and is US FDA approved for use in ADULTS with Alzheimer's Disorder. Its use in any other indication is currently "Off Label" and is at the discretion of the treating physician.

Studies are underway to establish its roles in other disorders, including in Autism Spectrum Disorder in children and adolescents.

As per "Memantine for the Treatment of Autism Spectrum Disorder: Overview of the Phase II Clinical Development Program (S42.009), Ephraim Katz, Jordan Lateiner, Allan Spera, Robert Palmer and Stephen Graham; Neurology April 8, 2014 vol. 82 no. 10 Supplement S42.009, as publised in (last accessed 6th June 2016)":
Memantine, an antagonist of N-methyl-D-aspartate glutamate receptors, is approved for patients with moderate to severe Alzheimer’s disease (AD), in whom it was shown to provide communication benefits. Memantine-associated benefits in communication and social behavior also have been observed in open-label autism trials.

Considering the investigational nature of the drug, only links and abstracts in public domain are being provided below without comments, so that the parent of an Autism affected child may be in a position to understand what is being attempted to help the child, and to make an informed choice about the use of this drug in his/her child, whose regulatory clinical trials in children are underway as at present.

There are many more papers like these. See for further information using the key words "memantine autism".
Click here to go to top Click here to go to Drugs Menu Click here for Home PageClick here to go to Main Home Page